Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides

Cyrille Mathieu1,2,3,4,5,* , Marcelo T. Augusto6,* , Stefan Niewiesk7, Branka Horvat1,2,3,4,5, Laura M. Palermo6,9, Giuseppina Sanna8,9,10, Silvia Madeddu8,9,10, Devra Huey7, Miguel A. R. B. Castanho6, Matteo Porotto8,9, Nuno C. Santos6 & Anne Moscona8,9,11,12

Human paramyxoviruses include global causes of lower respiratory disease like the parainfluenza viruses, as well as agents of lethal encephalitis like Nipah virus. Infection is initiated by viral glycoprotein-mediated fusion between viral and host cell membranes. Paramyxovirus viral fusion proteins (F) insert into the target cell membrane, and form a transient intermediate that pulls the viral and cell membranes together as two heptad-repeat regions refold to form a six-helix bundle structure that can be specifically targeted by fusion-inhibitory peptides. Antiviral potency can be improved by sequence modification and lipid conjugation, and by adding linkers between the protein and lipid components. We exploit the uniquely broad spectrum antiviral activity of a parainfluenza F-derived peptide sequence that inhibits both parainfluenza and Nipah viruses, to investigate the influence of peptide orientation and intervening linker length on the peptides' interaction with transitional states of F, solubility, membrane insertion kinetics, and protease sensitivity. We assessed the impact of these features on biodistribution and antiviral efficacy in vitro and in vivo. The engineering approach based on biophysical parameters resulted in a peptide that is a highly effective inhibitor of both paramyxoviruses and a set of criteria to be used for engineering broad spectrum antivirals for emerging paramyxoviruses.

Human parainfluenza viruses (HPIVs) are paramyxoviruses belonging to the respirovirus (HPIV1 and 3) or rubulavirus (HPIV2 and 4) genera that cause human respiratory diseases including bronchitis, bronchiolitis, and pneumonia in infants, children, or immune-compromised individuals. The HPIV species viruses are responsible for 30–40% of all acute respiratory tract infections in infants and children1. Nipah virus (NiV) is a zoonotic paramyxovirus of the henipavirus genus that represents a global health risk with broad, unpredictable pandemic potential. Infection with this virus is devastating, rapidly causing a generalized vasculitis leading to lethal encephalitis and serious respiratory infections. The common natural reservoirs of henipavirus genus members (including NiV, Hendra virus, Cedar virus and numerous newly identified species) are fruit bats2,3, but recent identification of rodent-origin henipa-like viruses that cause lethal respiratory disease in humans suggests that the range of natural mammalian hosts may be even broader4. Transmitted by air or food, its mechanism of infection is complex, and no drugs exist to prevent or treat infection. The recent human-to-human spread of NiV in Asia has raised the

1CIRI, International Center for Infectiology Research, 21 Avenue Tony Garnier, 69365 Lyon Cedex 07, France. 2INSERM U1111, Lyon, France. 3CNRS, UMR5308, Lyon, France. 4Université Lyon 1, Lyon, France. 5École Normale Supérieure de Lyon, Lyon, France. 6Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisbon, Portugal. 7Department of Veterinary Biosciences, College of Veterinary Medicine, Ohio State University, Columbus, USA. 8Department of Pediatrics, Columbia University Medical Center, 701 W. 168th St., New York, NY, USA. 9Center for Host-Pathogen Interaction, Columbia University Medical Center, 701 W. 168th St., New York, NY, USA. 10Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, Monserrato, Cagliari, Italy. 11Department of Microbiology & Immunology, Columbia University Medical Center, 701 W. 168th St., New York, NY, USA. 12Department of Physiology & Biophysics, Columbia University Medical Center, 701 W. 168th St., New York, NY, USA. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to N.C.S. (email: nsantos@fm.ul.pt) or A.M. (email: am939@cumc.columbia.edu)
real possibility of global spread. NiV and HPIV, while different in their associated diseases and geography, infect using similar mechanisms and are vulnerable to the same antiviral strategy.

Paramyxovirus infections are initiated by fusion between viral and host cell membranes. For HPIV3, NiV, and other paramyxoviruses, the surface glycoproteins play critical roles in the initial events of viral infection, mediating virion attachment to cells and fusion of the viral and cellular membranes. The viral fusion protein (F), upon insertion of the fusion peptide – formed after cleavage of the precursor F into its final fragment – into the host target cell membrane, forms a transient intermediate to pull the viral and cell membranes together. Two heptad-repeat regions that are present in each ectodomain of F refold to form a highly stable, antiparallel six-helix bundle structure that is coupled to membrane fusion. The structure required for this step can be specifically targeted by fusion-inhibitory peptides. The N-terminal repeat (HRN) is adjacent to the hydrophobic fusion peptide that inserts into the target cell membrane during the fusion process. The C-terminal repeat (HRC) immediately precedes the transmembrane domain. A folding-back of the F ectodomain drives the viral membrane towards the cell-associated fusion peptide to bring the two membranes into proximity, causing membrane fusion and viral entry.

Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion. We have shown the potential of modified fusion inhibitor peptides as NiV and HPIV antiviral agents, and showed that a sequence corresponding to the HRC domain of HPIV3 effectively inhibits both HPIV3 and NiV. Interhelical packing interactions in the post-fusion core of the NiV and HPIV3 F proteins are important determinants of viral entry and its inhibition. Fusion inhibitor peptides can be engineered at the level of these parameters, for optimal inhibition, increasing potency for both viruses. Conjugating cholesterol to a fusion inhibitor peptide enhances NiV antiviral activity up to 100-fold. PEG is soluble in both aqueous and organic media, and thus compatible with both plasma/extracellular fluids and membrane environment. Unlike alkyl linkers, PEG linkers do not cause aggregation and precipitation in the compounds in which they are incorporated. PEG is used to prevent non-specific adsorption onto hydrophobic surfaces, being non-toxic and non-immunogenic. The amino acid sequence and the modifications introduced into the peptides used for this study are shown in Fig. 1a. The entire set of peptides used here is based on a single peptide with the “VG” sequence, which has E549V and Q479G introduced into our published HPIV3-derived inhibitors. We have shown the potential of modified fusion inhibitor peptides as NiV and HPIV antiviral agents, and showed that a sequence corresponding to the HRC domain of HPIV3 effectively inhibits both HPIV3 and NiV. Interhelical packing interactions in the post-fusion core of the NiV and HPIV3 F proteins are important determinants of viral entry and its inhibition. Fusion inhibitor peptides can be engineered at the level of these parameters, for optimal inhibition, increasing potency for both viruses. Conjugating cholesterol to a fusion inhibitor peptide enhances NiV antiviral activity up to 100-fold. PEG is soluble in both aqueous and organic media, and thus compatible with both plasma/extracellular fluids and membrane environment. Unlike alkyl linkers, PEG linkers do not cause aggregation and precipitation in the compounds in which they are incorporated. PEG is used to prevent non-specific adsorption onto hydrophobic surfaces, being non-toxic and non-immunogenic. The amino acid sequence and the modifications introduced into the peptides used for this study are shown in Fig. 1a. The entire set of peptides used here is based on a single peptide with the “VG” sequence, which has E549V and Q479G introduced into our published HPIV3 F HRC-derived peptide. As for the previously reported NiV, HPIV3 and HIV inhibitors, reaction of the core sequence with a bromoacetyl derivative of cholesterol featuring a 4, 12 or 24-unit PEG spacer (PEG 4, 12 or 24) or on a single peptide with the “VG” sequence, which has E549V and Q479G introduced into our published HPIV3 HRC-derived peptide10. As for the previously reported NiV, HPIV3 and HIV inhibitors, reaction of the core sequence with a bromoacetyl derivative of cholesterol featuring a 4, 12 or 24-unit PEG spacer (PEG 4, 12 or 24) or without linker produced the cholesterol-conjugated monomer. The peptide with the “VG” sequence and a 24-unit PEG spacer before the cholesterol (called VG-PEG24-Chol) is shown in Fig. 1b.

Impact of PEG linker length and peptide orientation on HPIV3 and NiV cell-cell fusion. VG sequence peptides, either unconjugated or conjugated with cholesterol at the C-terminus, with linker lengths ranging from 0 to 24 PEG, were assessed for their ability to inhibit the cell-cell fusion mediated by viral glycoproteins. A quantitative cell-cell fusion assay based on β-galactosidase (β-gal) complementation was used as previously described11. Cholesterol conjugation improved peptide inhibition of cell-cell fusion mediated by HPIV3 and NiV glycoproteins, as expected. Incorporation of a PEG spacer significantly enhanced peptide efficacy against both viral glycoproteins. Increasing the linker length to PEG12 did not improve upon this result. The peptide with the longest spacer tested – PEG24 – showed the highest potency in this assay for both NiV and HPIV3 glycoproteins (Fig. 2a) suggesting that the relationship between spacer size and efficacy at inhibiting fusion is not linear.

The impact of the orientation of the peptide sequence on its ability to block cell-cell fusion was explored (Fig. 2b) by conjugating the lipid moiety and PEG spacer to either the C-terminus (e.g., VG-Chol) or the N-terminus (e.g., Chol-VG). All conjugated peptides showed potency against HPIV3 in this assay, with the N-terminally conjugated peptides significantly more effective at blocking fusion. For NiV, in contrast, Chol-VG has too little effect to determine an IC50 against NiV fusion. Only C-terminally conjugated peptides blocked the NiV glycoprotein-mediating fusion with high efficacy in the presence of the PEG linkers. The efficacy of the HPIV3 HRC-derived peptide against HPIV3 itself is higher when spacer and lipid are conjugated N-terminally, but this results in a loss of multipotency against NiV. These results suggest that both orientation of the peptide sequence and the length of the spacer are important for antiviral multipotency.

Results

We previously showed that HPIV3 HRC-derived sequences interact with HPIV3 F and NiV F HRN, that antiviral potency can be improved by sequence engineering and cholesterol conjugation, and that peptides without linkers between the protein and lipid component are less potent than those with a 4 polyethylene glycol (PEG) linker in the intervening region. Here we investigated the impact of the peptide orientation, as well as the influence of the PEG linker length, on the peptide antiviral efficacy. We focus on PEG linkers for exploration of these mechanisms since PEG features a number of characteristics that may be critical for tissue penetration of cholesterol-tagged peptides. PEG is soluble in both aqueous and organic media, and thus compatible with both plasma/extracellular fluids and membrane environment. Unlike alkyl linkers, PEG linkers do not cause aggregation and precipitation in the compounds in which they are incorporated. PEG is used to prevent non-specific adsorption onto hydrophobic surfaces, being non-toxic and non-immunogenic. The amino acid sequence and the modifications introduced into the peptides used for this study are shown in Fig. 1a. The entire set of peptides used here is based on a single peptide with the “VG” sequence, which has E549V and Q479G introduced into our published HPIV3 F HRC-derived peptide. As for the previously reported NiV, HPIV3 and HIV inhibitors, reaction of the core sequence with a bromoacetyl derivative of cholesterol featuring a 4, 12 or 24-unit PEG spacer (PEG 4, 12 or 24) or without linker produced the cholesterol-conjugated monomer. The peptide with the “VG” sequence and a 24-unit PEG spacer before the cholesterol (called VG-PEG24-Chol) is shown in Fig. 1b.
HPIV3 F HRC-derived peptides interact with uncleaved HPIV3 F. In previous studies, we used HRC-derived lipid-conjugated peptides to investigate the conformational flexibility of uncleaved F protein (F in its precursor protein form, with the hydrophobic fusion domain still buried)\textsuperscript{12}. The peptides bind to their corresponding HRN domains only when they are exposed by the unfolding of F, and serve as a tool to identify this exposure. For these experiments, peptides are attached to red blood cell (RBC) membranes via their cholesterol tails, and the RBCs are allowed to interact with cells expressing an uncleaved mutant of HPIV3 F (K108G) along with HN to engage the sialic acid receptor on the RBCs and initiate F-activation. The read-out for peptide interaction with the F protein’s HRN is adherence of the RBCs to the F-expressing cells. Since the uncleaved F cannot insert into the RBC membrane, this adherence occurs only via a peptide “bridge” formed when the peptide that is anchored to the RBC via its lipid tail also interacts with the HRN sequence of F expressed on the transfected cells\textsuperscript{12}. The uncleaved F has enough flexibility to unfold and expose the HRN domain upon activation by HN, but cannot fully extend into the transient “pre-hairpin” intermediate with its hydrophobic end inserted into the target membrane\textsuperscript{12}. For exploring peptide function, this assay provides a measure of the efficiency with which peptides bind at an early stage in the fusion process before the F-insertion step. Here we used the “peptide bridging” assay to assess the interaction of the series of modified VG peptides with the early transitional steps of F protein (Fig. 3). 293T cells co-expressing HPIV3 HN and uncleaved F (cleavage site mutant K108G, csm) were allowed to interact with receptor-bearing RBCs at 4 °C, then transferred to 37 °C in the presence of either C-terminally or N-terminally conjugated peptides (1 μM) with or without PEG4 linkers. Zanamivir, a sialic acid analog that blocks HN-receptor interaction\textsuperscript{13,14} was added after 1 h to disengage cells that were bound by HN-receptor engagement alone. The proportion of RBCs that were either free, reversibly bound by HN-receptor interaction (and therefore released by zanamivir), irreversibly bound by peptide bridging, or fused was quantified.

The unconjugated VG and the N-terminally conjugated Chol-VG peptides both failed to bind the HRC of uncleaved F in a manner sufficient to “bridge” the F-expressing cells and receptor-bearing cells; 80% of the RBCs were free and 20% were reversibly bound (attached only by HN-receptor engagement) in their presence. In contrast, VG-Chol (C-terminally lipid conjugated) peptide bridged the cell populations by attaching the F protein to the plasma membrane of the RBCs, as suggested by the 35% of irreversibly bound RBCs in the presence of this peptide. PEG spacers in the peptides led to an increase in bridging (as seen by irreversible RBC binding), for both the C-terminally and the N-terminally conjugated peptides, with the C-terminally conjugated peptides being significantly more effective at interacting with the early transitional intermediate of F. Since the spacer-less Chol-VG failed to bridge, this result suggests that the spacer permits the N-terminally conjugated peptide to insert into the RBC membrane. Of the peptides tested, VG-PEG4-Chol showed the most effective bridging, more than 50% irreversible retention, while the peptide that was most effective at inhibiting fusion inhibition, VG-PEG24-Chol (Fig. 2), looks similar to VG-Chol, a far less effective inhibitor. As further explored below, this may relate to the more dynamic membrane insertion of VG-PEG24-Chol, allowing release of the “bridge” mediated by this peptide and release of attached RBCs.

PEG linkers improve the solubility of HPIV3 derived peptides. The aggregation and lipid-binding properties of VG peptides were assessed based on the intrinsic fluorescence of their tryptophan (Trp) residues (Fig. 4a). The fluorescence excitation spectra of VG peptides in buffer nearly overlap that of free Trp. Regarding the fluorescence emission spectra, only the untagged peptide VG showed a close overlap with Trp spectrum.
Figure 2. Influence of spacer length and sequence orientation on the inhibition of HPIV3 HN/F and NiV G/F mediated fusion by HPIV3 F derived HRC peptides. Fusion of HPIV3 HN/F (panel a left) or NiV G/F-coexpressing cells (panel a right) with 293T cells in the presence of serial dilutions of VG, VG-Chol, VG-PEG4-Chol, VG-PEG24-Chol was quantified at 1 h, using a β-galactosidase complementation assay. (b) The same assay was used to quantify fusion in the presence of N-terminally versus C-terminally conjugated peptides. Results are presented as percent reduction in luminescence (y-axis) compared with no treatment. Each point is the mean ± s.d. of results with n = 3 experiments.

Figure 3. Spacer and peptide orientation influence on the ability of HPIV3 F HRC cholesterol-tagged peptides to capture fusion intermediates of native F before fusion peptide insertion in the target membrane. When HN is receptor bound, unprocessed F (K108G; cleavage site mutant csm) may be activated to a transient intermediate that is captured by cholesterol-conjugated peptides. Monolayers of cells coexpressing HN and unprocessed F (csm) were interacted with receptor-bearing RBCs at 4 °C. Upon transfer to 37 °C, medium containing either no peptide or 1 μM peptide was added. Zanamivir was added to disengage HN from its receptor after 1 h, and the values on the y-axis reflect the quantitation of RBCs that were directly released (black), reversibly bound by HN-receptor interaction (gray), irreversibly bound (light gray), or fused (white). The values are means (±standard deviations) of results from three experiments.
Cholesterol-containing VG peptides presented a blue-shift on the emission maximum, indicating that the Trp residue of these conjugates are in a more hydrophobic environment, as previously observed for different cholesterol-tagged HIV fusion inhibitor peptides.

Fusion inhibitor aggregation propensity was tested using the fluorescent dye 1-anilino-8-naphthalene sulfonate (ANS). In the presence of hydrophobic pockets, there is a significant increase in the ANS quantum yield and a blue-shift in the maximum emission peak is observed. As expected, the untagged peptide VG was unable to form aggregates (Fig. 4b). Titration of ANS with VG-Chol, VG-PEG4-Chol and VG-PEG24-Chol at pH 7.4 led to a significant blue-shift of 67 nm, 63 nm and 58 nm, respectively (data not shown). This is indicative that all cholesterol-tagged peptides form aggregates when dissolved in HEPES 10 mM pH 7.4 NaCl 150 mM buffer. VG-Chol, VG-PEG4-Chol and VG-PEG24-Chol were compared in order to test the PEG spacer' effect on peptide aggregation (Fig. 4b). The longer the PEG spacer the lower the aggregation observed. This variation is more evident upon comparing VG-Chol with VG-PEG24-Chol (Fig. 4b).

PEG linkers enhance HRC-derived peptides’ insertion in lipid membranes. To quantify peptide-membrane affinity and assess the changes induced by cholesterol conjugation, we evaluated the ability of VG series peptides to induce changes on the surface pressure of lipid monolayers (Fig. 5).
VG peptides are able to induce changes on the surface pressure of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) monolayers. Only VG and the peptide solvent control with dimethyl sulfoxide (DMSO) showed no changes on the lipid monolayer. VG-PEG24-Chol was the most active peptide by inducing the largest change on the monolayer surface pressure, with ΔΠmax ~ 4 mN/m (Fig. 5b). Increasing concentrations of VG peptides led to an increase on the surface pressure, until a plateau of peptide saturation on the monolayer is reached. These data allow the use of equation (1) to calculate the dissociation constant, \( K_d \). Despite the similar affinity for POPC (Fig. 5d), VG peptides presented very distinct kinetics towards this lipid (Fig. 5c). Using equation (2), a higher insertion rate, \( k_i \), was observed for VG-PEG24-Chol (7.4 × 10⁻⁴ s⁻¹), in comparison with VG-PEG4-Chol and VG-Chol (Fig. 5c,d). A similar kinetic behavior was observed for a mixture of POPC with 33% of cholesterol, which represents more ordered domains and the membranes of some cells with high cholesterol content, such as RBCs (data not shown).

RBCs were selected as cell model to test peptide-cell membrane affinity. However, a direct measurement of the peptide tryptophan fluorescence is impracticable with cells. As an indirect reporter, we used the lipophilic fluorescent probe di-8-ANEPPS to measure the interaction of the peptides with the cell membranes. RBCs were labeled with this probe as previously reported⁰¹⁵–¹⁷. The VG peptides were incubated with the RBCs during 1 h. The cholesterol-tagged peptides were able to induce changes on the membrane dipole potential sensed by di-8-ANEPPS (Fig. 6). The VG peptide and the control DMSO did not cause any change on the membrane dipole potential. As a quantitative measure of the interaction of VG peptides with membranes, the ratio \( R \) was measured for a range of peptide concentrations. This ratio decreases upon increasing the concentration of cholesterol-tagged peptides, following a hyperbolic curve. These curves were fitted with equation (3), allowing determination of the dissociation constant, \( K_d \). VG-PEG24-Chol showed a higher affinity (\( K_d = 0.33 \mu \text{M} \)) in comparison with VG-Chol (\( K_d = 0.54 \mu \text{M} \)) and VG-PEG4-Chol (\( K_d = 0.44 \mu \text{M} \)) (Fig. 6B).

**Protease sensitivity of HPIV3 derived peptides.** We recently tested the hypothesis that while lipid conjugation decreases protease sensitivity, addition of PEG linkers increases protease sensitivity. Figure 7 shows VG series peptides incubated in the absence (−) or presence (+) of trypsin, at 0.025 μg/μl for 1 h at 0°C or 37°C. The products of the reaction were subjected to reducing SDS-page gels and silver stained.

### Table 1

| Peptides | \( K_d \) (μM) | \( R_{\text{min, norm}} \) |
|----------|--------------|-----------------|
| VG       | -            | -               |
| VG-Chol  | 0.54 ± 0.20  | -0.30 ± 0.03    |
| VG-PEG4-Chol | 0.44 ± 0.12  | -0.39 ± 0.02    |
| VG-PEG24-Chol | 0.33 ± 0.06  | -0.37 ± 0.01    |

**Figure 6.** Peptide affinity towards RBCs assessed by di-8-ANEPPS fluorescence. (a) The dependence of the ratio \( R \) on VG (black), VG-Chol (blue), VG-PEG4-Chol (orange) and VGPEG24-Chol (green) concentrations for RBCs was analyzed by a single binding site model (dashed lines) in order to quantify the apparent dissociation constants, \( K_d \). The \( R \) values were normalized for the initial value of zero peptide concentration. (b) The \( K_d \) values represent the mean ± s.e.m. (n = 4). \( R_{\text{min}} \) is the asymptotic minimum value of \( R \).

**Figure 7.** Protease sensitivity of HPIV3 derived peptides. The indicated peptides were incubated in the absence (−) or presence (+) of trypsin, at 0.025 μg/μl for 1 h at 0°C or 37°C. The products of the reaction were subjected to reducing SDS-page gels and silver stained.
the cholesterol (with or without PEG linker) is conjugated to the N-terminus, the peptides were significantly more resistant to protease degradation. Panel C shows that even at 37° the peptides with N-terminal tags are not degraded.

Impact of PEG spacer length on the inhibition of HPIV3 and NiV infection plaque formation in monolayer cultured cells. To explore the significance of these observations in the context of authentic virus, we assessed the efficacy of VG series peptides at inhibiting infection by HPIV3 and live NiV, in cell culture (Fig. 8). As expected, cholesterol conjugation significantly ameliorated the peptide efficacy against both viruses, as measured by reduction in plaque formation. While the presence of the PEG4 linker had no impact on the peptide’s IC90 against HPIV3 (~1 nM) it reduced the IC90 for inhibition of NiV (from 300 nM to 50 nM). An increase in spacer length to PEG24 led to a significant increase of efficacy against both HPIV3 (IC90 ~ 0.1 nM) and NiV (IC90 ~ 2 nM). In addition, we evaluated the toxicity and specificity of the peptides. Table 1 shows that toxicity of VG-PEG24-Chol on cells appears only when we reach a concentration of 1000 nM (10,000 × IC90); toxicity of the other peptides in the series was even lower. Since VG-PEG24-Chol, although quite non-toxic, had the highest toxicity of all the peptides in this series, we chose this peptide for an experiment designed to assess specificity of inhibition. We compared the antiviral effect of VG-PEG24-Chol to PEG24-Chol conjugated peptides that are effective against measles, influenza virus, and feline immunodeficiency virus. None of these peptides were inhibitory for HPIV3, supporting the notion that potency depends on the presence of the HPIV3 peptide sequence, not simply on the linker or lipid moiety (Table 1).

Impact of PEG spacer length on the inhibition of HPIV3 in HAE. HAE cultures are an authentic model of human lung that can be used to evaluate features of infection and antiviral efficacy. Peptide efficacy in HAE seems to correlate with in vivo efficacy. Therefore we now assessed efficacy of VG peptides in HAE, using this authentic lung model to compare those peptides that have the best potency in monolayer culture and no toxicity at a 100 μM concentration in HAE cultures. VG-PEG4-Chol, Chol-PEG4-VG, and VG-PEG24-Chol

![Figure 8. Spacer length impacts VG peptide efficacy against both HPIV3 clinical isolates (CI) and NiV.](image)

(a) Vero cell monolayers were infected with HPIV3 at a multiplicity of infection (m.o.i.) of 2.5 × 10⁻³, in the presence of increasing concentrations of the peptide. After a 90-min incubation at 37 °C, cells were overlaid with methylcellulose, and plaques were immunostained and counted after 24 h. The percent inhibition of viral entry (compared to results for control cells infected in the absence of inhibitors) is shown as a function of the (log-scale) concentration of peptide (n = 3 separate experiments). (b) Vero cell monolayers were infected with wild type NiV at an m.o.i. of 2.5 × 10⁻³ in the presence of increasing concentrations of peptides. After 1 h incubation at 37 °C, cells were overlaid with methylcellulose, and plaques were stained and counted after 96 h. The percent inhibition of viral entry (compared to results for control cells infected in the absence of inhibitors) is shown as a function of the (log-scale) concentration of peptide. Data points are means ± s.d. (n = 6 separate experiments).

| Peptide | Cytotoxicity in monolayer culture | Efficacy in plaque reduction assay vs. HPIV3 |
|---------|----------------------------------|------------------------------------------|
|         | CC50(nM)a                         | IC90(nM)b                                | IC50(nM)b |
| VG      | >10,000                           | 280 ± 247                                | 1         |
| VG-Chol | 10,000                            | 0.7 ± 0.26                               | 0.015 ± 0.07 |
| VG-PEG4-Chol | 4,500                      | 0.7 ± 0.007                               | 0.03 ± 0.04 |
| VG-PEG24-Chol | 1,300                  | 0.1 ± 0.0003                             | 0.007 ± 0.007 |
| Chol-VG | 9,000                            | 1.7 ± 0.42                               | 0.06 ± 0.035 |
| Chol-PEG4-VG | >10,000                  | 0.1 ± 0.0001                             | <0.0007 |
| HRCMV PEG 24 Chol | 9,000                   | >9,000                                   | >9,000 |
| HRCMV PEG 24 Chol | 2,000                  | >2,000                                   | >2,000 |
| HAFLU PEG 24 Chol | 3,000                   | >3,500                                   | >3,500 |

Table 1. Cytotoxicity, in vitro activity, and specificity of fusion inhibitory peptides. aCompound concentration required to reduce the viability of mock-infected Vero cells by 50%, as determined by MTT. bCompound concentration required to achieve 50% or 90% plaque reduction for HPIV3.
Figure 9. Biodistribution of cholesterol-tagged VG-PEG24-Chol peptide. Golden hamsters were injected with 2 mg/kg of VG-PEG24-Chol peptide intraperitoneally (i.p.). (a) At indicated times (x-axis) the animals (n = 3/data point) were sacrificed, and the peptide concentrations in plasma, lung, and brain were quantitated. The ordinate values are means (±s.d.) of results from three animals. (b,c) Immunofluorescent staining of VG-PEG24-Chol (in green) in the brain of hamsters 24 h after i.p. administration. Nuclei were counterstained using DAPI. Peptide staining is absent from untreated animals (b). VG-PEG24-Chol peptide (green) is present in the brain parenchyma of treated hamsters (c), confirming its ability to reach the CNS.

were compared for their ability to inhibit infection in HAE at 10 μM. A single dose of 10 μM of VG-PEG4-Chol decreased the viral titer of HPIV3 by approximately two logs at day 2 after infection and approximately one log at day 5. For Chol-PEG4-VG and VG-PEG24-Chol, no virus was produced at any time after infection, indicating that viral infection was completely inhibited at this concentration in HAE. When the inhibitors were given in a single dose of 1 μM, VG-PEG24-Chol resulted in complete inhibition of infection; however, both Chol-PEG4-VG and VG-PEG4-Chol showed only partial inhibition (data not shown).

Peptide biodistribution in vivo. The utility of peptides as antivirals depends in large part on biodistribution and availability at the site of infection. We have previously assessed the biodistribution of the HPIV3 derived peptides in hamsters and cotton rats that serve as the model for NiV and HPIV3 infection6,19. Here, we assessed the half-life and distribution of the VG-PEG24-Chol peptide (2 mg/kg, i.p.) and detected free peptide in the serum at 8 h, with concentration peaking at 120 nM before dropping after 24 h, accompanied by peptide detection at 24 h in organs (Fig. 9a). No peptide was detected in the urine, suggesting the peptide is not eliminated intact (data not shown). Immuno-histofluorescence showed that peptide is present in brain parenchyma 24 h after administration, confirming its ability to reach the CNS (Fig. 9b and c). We had previously observed CNS localization not only for the HPIV3 peptide6 but also for measles virus (MV) F sequence derived peptides11, suggesting that this feature does not require a highly specific peptide sequence.

Peptide inhibition of HPIV3 and NiV infection in vivo. Having established peptide biodistribution in cotton rats and hamsters, we assessed VG-PEG24-Chol efficacy against HPIV3 and NiV infection in the corresponding models. Peptide administered s.q. significantly decreased the viral load in cotton rat lungs 3 days after intranasal infection with HPIV3 (p = 0.0286, using Mann-Whitney U-Test; Fig. 10a). For NiV, i.p. VG-PEG24-Chol peptide administration daily from day-1 to day 10 after NiV inoculation (100LD50, i.p.) significantly improved the survival of hamsters given a lethal infection inoculum (p = 0.0016, using Mantel-Cox test; Fig. 10b). These results suggest that the peptide identified as bearing optimal biophysical properties for in vitro inhibition is promising as an inhibitor of infection and is effective against both viruses in vivo.

Discussion

We have shown that specific, predictable features are important for paramyxovirus antiviral peptide efficacy, and we have now begun to pinpoint the contributions to efficacy of amino acid sequence and lipid moiety, as well as linker length, solubility and other biophysical features. We build upon the remarkable foundation of a peptide sequence derived from the HRC domain of one paramyxovirus, HPIV3, which inhibits both HPIV3 and the quite different paramyxovirus, NiV.

The fluorescence spectra of the VG series peptides (Fig. 4) showed that the conjugation of cholesterol leads to a change on the microenvironment of the fluorescent tryptophan residues. These results indicate a more hydrophobic setting surrounding the tryptophan, suggesting a possible peptide aggregation. The data from the ANS experiments (Fig. 4) confirmed this hypothesis, showing that incorporating PEG24 on the VG series peptides partially decreases aggregation. In a recent work on PEGylation, it was reported that the conjugation of PEG to Aβ peptides enhanced peptide solubility and led to concentration-dependent reversible fibrillization16.

A longer PEG linker promoted a faster kinetic towards lipid monolayers as observed in Fig. 5. In addition to the presence of cholesterol, the length of the linker was also a key factor contributing to the membrane driving force. In agreement with previous results, a less aggregated peptide could diffuse more easily towards the cell membrane, which is beneficial for peptide local concentration.

A high affinity for RBCs membrane was observed for VG-PEG24-Chol (Fig. 6), corroborating the lipid monolayers and the aggregation experiments. We have previously shown that cholesterol conjugation to HIV-1 fusion inhibitor peptides also promotes the interaction with RBCs15,16. Peptides lacking membrane binding domains are
optimal candidates for cholesterol tagging, as their antiviral activity is boosted after that. The inclusion of PEG spacers seems to reduce peptide aggregation and induce a fast kinetics towards cell membranes.

When we correlate these biophysical analyses with antiviral activity, data suggest that a synergic combined effect of the membranotropic behavior provided by the cholesterol addition and the increase in solubility (decreased tendency to aggregate) conferred by PEG addition explains the antiviral pattern found for these compounds. The optimal peptide must have the correct balance between membrane tropism and solubility.

The most effective peptides we tested for HPIV3 and NiV are those with the fastest kinetics of insertion and release from membranes, a feature that correlates with the PEG linker length. However, a long PEG linker is expected to cause the peptides to be more exposed to the aqueous environment\(^\text{15,16}\), and more sensitive to protease degradation, as shown in Fig. 7, and thereby to have a shorter half-life. In other words, it seems that since the pocket binding domain of the antiviral peptide is more exposed it is more potent, but also more sensitive to protease. This could potentially explain why the level of VG-PEG24-Chol in the brain and serum is relatively low compared to our previous data for other peptides\(^\text{6,19}\). The finding that the longer PEG increases protease sensitivity is part of the complexity of identifying ideal candidates for in vivo testing; one must identify a balance between absolute antiviral potency and stability. In order to be able to take advantage of the antiviral potency conferred by the longer linker (PEG24) we are now addressing ways to reduce protease sensitivity, for example by modifying the protein backbone.

Surprisingly, when the cholesterol (with or without PEG linker) is conjugated to the N-term, the peptides are significantly more resistant to protease degradation (Fig. 7). Lipid conjugation is known to enhance the helicity of peptides\(^\text{21}\), and we speculate that the differential effect of conjugating at the N- and C-terminals may relate to the fact that the N-term of this peptide is less structured than the C-term\(^\text{6,22}\), and therefore more likely to be protease sensitive. Conjugation at this less-structured terminus may thereby be protective either due to the effects of aggregation or of enhanced helicity.

While until now we have focused the antiviral strategy on the peptides with lipid conjugated to the C-term because they were far more potent inhibitors compared to those with lipid conjugation at the N-term\(^\text{8}\), here we showed that by adding a PEG linker between the lipid and the peptide sequence at the N-term, the N-terminally conjugated peptides are rendered more potent against the virus from which they are derived. The efficacy of N-terminally lipid conjugated fusion inhibitory peptides has been studied for both Ebola\(^\text{21}\) and Newcastle Disease virus\(^\text{63}\). In the case of Newcastle Disease virus, Li et al. showed that N-terminal cholesterol conjugation enhanced the potency of inhibitory peptides and allowed them to penetrate the CNS, while the effect of addition of a PEG3 linker between the N-terminal cholesterol and the inhibitory peptide was less clear. In our case, the linker between N-terminal cholesterol and peptide significantly enhances anti-HPIV3 potency, while abrogating broad-spectrum antiviral activity. We speculate that without a flexible linker, the N-terminally conjugated peptides could not attain the proper position for interacting with the target region on F - or could do so only when not anchored in the membrane or later in the fusion process (after fusion peptide insertion and during the refolding step). The mechanism basis for the negative effect on inhibition of NiV remains to be explored. As shown schematically in Fig. 11, a flexible PEG linker allows for freedom of orientation in order to align properly with the target HRN domain, or for more dynamic kinetic of insertion into the membrane. This may be an advantage not only for interacting with the F protein once it has inserted into the host cell membrane (at which point it is a target for both lipid-conjugated and unconjugated peptide inhibitors)\(^\text{8}\) but also for interacting with the pre-insertion F. The pre-insertion F protein is shown in Fig. 11 as extended into a transient intermediate in panel
a; panels b, c, and d depict the C-terminally conjugated VG-Chol peptides with each linker length interacting with this pre-insertion step in fusion, suggesting that the longer linker may allow for optimal alignment between the peptide and the HRN on F. The peptide with a PEG-24 linker (Fig. 11d,e) has been shown to be the most effective inhibitor but to less potently capture early intermediates of F activation (see Fig. 3). Based on the biophysical data showing the increased dynamic membrane interaction for this peptide, we speculate that this peptide may flip between the target host cell (panel d) and the viral membrane (panel e), reducing observed capture of F while increasing efficacy. These mechanisms could also explain why the N-terminally conjugated peptides may be rendered effective by a long linker which could either optimize alignment with F or permit activity from both cell and viral surfaces. In this study, we focused on peptides with the lipid conjugation at the C-terminus because this approach led to conservation of the broad antiviral spectrum—a primary goal of this work. However in light of the advantage shown by the N-terminally conjugated peptides in terms of protease sensitivity, we will also explore the effect of longer PEG linkers on potency and protease sensitivity of N-linked peptides and determine the basis for the difference in antiviral spectrum conferred by orientation of the lipid moiety. Future studies will address the issue of protease sensitivity, in addition to varying the location of the lipophilic moiety, by modifying the amino acid backbone so as to render it less protease sensitive.

The biophysical data shown here lead to several conclusions that can now be applied to peptide design. The lipid moiety drives the interaction between the peptides and the lipid membrane, and is a determinant for the affinity of the compounds toward the membrane. As the cholesterol moiety is conserved among the active compounds we assessed here, it may explain the similar dissociation constants obtained for the different molecules. However, we observed significant differences in the kinetic behavior of each peptide. VG-PEG24-Chol exhibits the fastest kinetics of membrane insertion, followed by VG-PEG4-Chol. The addition of cholesterol to the lipid monolayers boosts the kinetic rate constant of all peptides; only the most potent peptides interact well with membranes in the absence of cholesterol in the target membrane (data not shown). We speculate that the linear membranotropic (association/dissociation from membrane) properties associated with the effective peptides also affect biodistribution and therefore in vivo efficacy, as they may circulate in association with RBCs. We assessed the serum and RBCs from peptide-dosed animals, and found that peptides are present both in the plasma and on the surface of the RBCs (data not shown). Association with RBCs may be one mechanism whereby the lipid moieties enhance half-life in vivo. Addition of PEG linkers, while significantly enhancing potency, confers protease sensitivity, an issue that may be mitigated by measures including N-terminal conjugation. This understanding of the set of properties that correlate with the peptides’ potency permits enhancement of antiviral effect of HPIV3-derived peptides for both HPIV3 and NiV. In addition to guiding peptide design, these principles will be used to obtain the optimal balance of orientation, lipid moiety, valency, linker length, and amino acid sequence with the goal of broad spectrum activity for paramyxoviruses.

**Methods**

**Cells.**  293T (human kidney epithelial), CV-1 and Vero E6 cells were obtain from ATCC and were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum and antibiotics at 37°C and 5% CO2. All cells were tested negative for mycoplasma in MycoAlert™ Mycoplasma Detection Kit (Lonza).

**Peptide synthesis.**  All peptides were produced by standard Fmoc-solid phase methods. The cholesterol moiety was attached to the peptide via chemoselective reaction between the thiol group of an extra cysteine residue, added C-terminally to the sequence, and a bromoacetyl derivative of cholesterol, as previously described.

**Viruses.**  HPIV3 clinical isolate virus (CI) was obtained from the Clinical Microbiology Laboratories at New York Presbyterian Hospital and grown in human airway epithelium (HAE) at an air-liquid interface for only one
Pseudotyped viruses were generated using VSV-ΔG-RFP, a recombinant VSV derived from the cDNA of VSV Indiana in which the G gene is replaced with the Δv-RFP gene (RFP). Pseudotypes with NiV F and G were generated as described previously. Briefly, 293T cells were transfected with plasmid encoding VSV-G or NiV-F/G. Five hours post-transfection, the dishes were washed and infected (multiplicity of infection [MOI] of 0.5) with VSV-ΔG-RFP complemented with VSV-G. Supernatant fluid containing pseudotyped virus (NiV F/G or VSV-G) was collected 18 h post-infection and stored at −80°C.

NiV isolated from the cerebrospinal fluid of a patient was received from Dr. K.B. Chua and Dr. S.K. Lam (University of Malaya, Kuala Lumpur, Malaysia). NiV was prepared by infecting Vero-E6 cells as previously described, in the INSERM Jean Mérieux biosafety level 4 (BSL-4) laboratory in Lyon, France.

**β-Gal complementation-based fusion assay.** We previously adapted a fusion assay based on alpha complementation of β-galactosidase (β-Gal)27,38. In this assay, receptor-bearing cells expressing the omega peptide of β-Gal are mixed with cells co-expressing envelope glycoproteins and the alpha peptide of β-Gal, and cell fusion leads to alpha-omega complementation. Fusion is stopped by lysing the cells and, after addition of the substrate (®The Tropix Galacto-Star™ chemiluminescent reporter assay system, Applied Biosystem), fusion is quantified on a Spectramax M5 microplate reader. In the overnight fusion assay, cells expressing both alpha and omega peptides of β-Gal were co-cultured for up to 20 h.

**Pseudotyped entry assay mimicking multicycle replication.** As described previously29,30, NiV F/G glycoproteins were pseudotyped onto VSV-ΔG-RFP and the resulting pseudotyped viruses were used to infect NiV F/G-expressing cells, at an MOI of 0.125, for simulation of multicycle replication. RFP production at 24, 48, 72 and 96 h was analyzed on a microplate fluorescence reader (Spectramax M5). For detecting RFP expression levels, the wells were read by excitation at 535-nm and emission at 579-nm. For the detection of YFP expression, the wells were read by excitation at 510-nm and emission at 535-nm.

**Assay for triggering of F-mediated fusion using uncleaved HPIV3 F K108G: receptor retention, receptor release, and F retention by peptides.** Monolayers of 293T cells were transfected to transiently express the cleavage site mutant HPIV3 F (K108G) and WT HH in the presence of neuraminidase 40 mU/ml, overnight. The next day, cells were washed and incubated with neuraminidase 40 mU/ml and cyclohexamide 1:1000 (100 μg/ml) for 1 h, at 37°C. Then, cells were washed and incubated with 1% RBC suspensions in CO2 independent medium (Life Technology) at pH 7, for 30 min, at 4°C. After rinsing to remove unbound RBCs with CO2 independent medium, 1 μM of peptide was added, and the plates were placed at 37°C for 1 h. Zanamivir was added at a final concentration of 2 μM, and the plates were left at 37°C until the complete release of RBCs in the non-treated samples. Plates were rocked, and the liquid phase was collected in V-bottomed tubes for measurement of released RBCs. The monolayers were incubated at 4°C with 200 ml of RBC lysis solution (lysis of unfused RBCs with NH4Cl removes the RBCs whose membranes have not fused with HN/F-coexpressing cells).

**Lipids.** POPC was purchased from Avanti Polar Lipids (Alabaster, AL, USA), while cholesterol (Chol) was from Sigma.

**Fluorescence spectroscopy measurements.** VG peptides contain one tryptophan residue, intrinsically fluorescent, which makes fluorescence spectroscopy methodologies suitable tools to follow these molecules. Membrane dipole potential studies were carried out in a Varian Cary Eclipse fluorescence spectrophotometer (Mulgrave, Australia). Peptide aggregation studies were evaluated in a FLS920 series fluorescence spectrophotometer (Edinburgh Instruments, Livingston, UK). L-Tryptophan, HEPES and NaCl were from Merck (Darmstadt, Germany). The working buffer used throughout the studies was HEPES 10 mM pH 7.4 in NaCl 150 mM16,31,32.

Intrinsic fluorescence measurements of VG peptides and tryptophan (for the sake of comparison) were performed with an excitation wavelength of 280 nm and a starting emission wavelength of 300 to 450 nm. The excitation spectra of the same species was obtained from 220 to 300 nm, with a fixed emission wavelength of 350 nm.

ANS fluorescence emission spectra were obtained from 400 to 600 nm, with an excitation wavelength of 369 nm. Typical spectral bandwidths were 5 nm for excitation and 10 nm for emission. Excitation and emission spectra were corrected for wavelength-dependent instrumental factors35. Emission was also corrected for successive dilutions, scatter and simultaneous light absorptions of quencher and fluorophore44. All fluorescence measurements were performed at approximately 25°C.

**Aggregation followed by ANS fluorescence.** The effect of peptide concentration on VG, VG-Chol, VG-PEG4-Chol or VG-PEG24-Chol aggregation was followed by ANS fluorescence, with excitation at 369 nm. The intensity of fluorescence emission was collect from 400 to 600 nm. A final ANS concentration of 12.8 μM was used throughout the experiments and titrated with peptides stock solution to yield a final peptide concentration in the range of 0–8 μM. 2 way-ANOVA statistical analysis was applied to distinguish the influence of PEG linkers in peptide aggregation.
Surface pressure. Changes on the surface pressure of lipid monolayers induced by VG, VG-Chol, VG-PEG4-Chol or VG-PEG24-Chol were measured in a Langmuir-Blodgett trough NIMA ST900 (Coventry, UK), at constant temperature (25 ± 0.5 °C).

Briefly, a solution of lipids in chloroform was spread on a Teflon trough of fixed area until it reaches a surface pressure of 23 ± 1 mN/m. The lipid used in this study forms monolayers upon spreading on the air–water interface. Peptide solutions were injected in the subphase and the changes on the surface pressure were followed during the time necessary to reach a constant value. The surface pressure of an air-water interface upon injecting the largest concentration of each peptide used throughout the studies was always below 15 mN/m (data not shown). For this reason, the lowest initial surface pressure of the lipid monolayers before the addition of the peptides to the subphase was above that value. In this condition, the changes in surface pressure observed upon the injection of the peptide can be attributed to an effect of the peptide on the monolayer interfacial tension.

The dissociation constant \((K_p)\) was calculated from the adsorption Langmuir isotherm:

\[
\Delta \Pi = \frac{\Delta \Pi_{\text{max}} [\text{peptide}]}{K_d + [\text{peptide}]}
\]

where \(\Delta \Pi\) are the changes of surface pressure, \(\Delta \Pi_{\text{max}}\) is the maximum change of pressure achieved and [peptide] is the peptide concentration.

The insertion rate constant \((k)\) was calculated from the equation:

\[
\Delta \Pi = -e^{-kt} \Delta \Pi_{\text{max}} + \Delta \Pi_{\text{max}}
\]

Membrane dipole potential assessed by di-8-ANEPPS. Isolation of RBCs from human blood samples was approved by the joint ethics committee of Faculdade de Medicina da Universidade de Lisboa and Hospital de Santa Maria. These samples were obtained from healthy volunteers at the Instituto Português do Sangue (Lisbon, Portugal). All patients provided written informed consent to be enrolled in the study. In addition, all methods were performed in accordance with the relevant guidelines and regulations.

RBCs were labeled with the membrane dipole potential sensitive probe di-8-ANEPPS (Invitrogen, Carlsbad, CA, USA). Briefly, blood samples were centrifuged at 1200 × g for 10 min, plasma and buffy-coat were removed, and remaining RBCs were washed twice with HEPES buffer. RBCs at 1% hematocrit were incubated in buffer supplemented with 0.05% (m/v) Pluronic F-127 (Sigma) and di-8-ANEPPS 10 μM during 1 h17,34. The unbound probe in the labeled cells was washed with Pluronic-free buffer on two centrifugation cycles. VG, VG-cholesterol, VG-PEG4-Chol and VG-PEG24-Chol were incubated with erythrocytes at 0.02% hematocrit, during 1 h, with gentle agitation, before fluorescence measurements.

Excitation spectra and the ratio of intensities at the excitation wavelengths 455 and 525 nm \((R = I_{455}/I_{525})\) were obtained with emission set at 670 nm, in order to avoid membrane fluidity-related artifacts39. Excitation and emission slits for these measurements were set to 5 and 10 nm, respectively. The variation of \(R\) with the peptide concentration was analyzed by a single binding site model40,41:

\[
\frac{R}{R_0} = 1 + \frac{R_{\text{min}}}{K_d} \frac{[\text{peptide}]}{K_p + [\text{peptide}]}
\]

with \(R\) values normalized for \(R_0\), the value in the absence of peptide. \(R_{\text{min}}\) defines the asymptotic minimum value of \(R\) and \(K_p\) is the apparent dissociation constant.

Antiviral activity against live HPIV3. Peptide activity against HPIV3 was determined by plaque reduction assays in infected cell monolayers15. IC50 of inhibition was calculated using Graph Pad Prism 5 software. Data were expressed as mean ± standard deviation (s.d.) \((n = 3\) separated experiments).

Antiviral activity against live Nipah virus. In the plaque reduction assay, serial dilutions of peptides in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) were added to reporter cell monolayers of Vero E6 cells (in 6-well plates, 106 cells/well) for 1 h at 37 °C, 5% CO2. Then, 200 pfu of NiV were added to the supernatant fluid of the Vero cell culture and incubated for 1 h at 37 °C. Supernatant fluids were then replaced by 2 ml of 1.6% of carboxymethylcellulose in DMEM containing 3% of FCS. Plates were incubated for 4 days at 37 °C, 5% CO2. Plates were developed using a central plaque assay, as previously described26. IC50 of inhibition were calculated using Graph Pad Prism 5 software. Data were expressed as mean ± s.d. \((n = 6\) separated experiments).

Cell viability assay. Vero cells were seeded in 96-well plates at a density of 5 × 103 cells/well, in DMEM (Gibco) supplemented with 10% FCS and 2 mM L-glutamine and allowed to form confluent monolayers overnight at 37 °C in a humidified CO2 (5%) atmosphere. Cell cultures were then incubated at 37 °C in the absence or presence of serial dilutions of peptides. Cell viability was determined after 24 hrs at 37 °C by the MTT method (Vybrant® MTT Cell Proliferation Assay Kit V-13154).

HAE cultures. The EpAirway AIR-100 system (MatTek Corporation) consists of normal human-derived tracheo/bronchial epithelial cells that have been cultured to form a pseudostratified, highly differentiated mucociliary epithelium closely resembling that of epithelial tissue in vivo. Upon receipt from the manufacturer, HAE cultures were transferred to 6-well plates (containing 0.9 ml medium per well) with the apical surface remaining exposed to air and incubated at 37 °C in 5% CO2.
Peptide efficacy assessment in HAE cultures. HAE cultures were infected by applying 100 µl of EpiAirway medium containing 4,000 PFU of HPIV3 with or without peptide to the apical surface for 90 min at 37 °C. The medium containing the inoculum was removed, and cultures were placed at 37 °C and fed each day with 0.9 ml medium via the basolateral surface. Viruses were harvested by adding 200 µl medium per well to the HAE cultures’ apical surface and allowed to equilibrate for 30 min at 37 °C. The suspension was then collected, and viral titers were determined as previously described18. Viral collection was performed sequentially with the same wells of cells on each day post infection.

Protease sensitivity of HPIV3 derived peptides. For the trypsin digestion, 1 µg of each peptide was treated with 0.025 µg of trypsin in 10 µl of 1X PBS. Peptide solutions were then incubated at 0 °C or 37 °C for 30 minutes. Following incubation, 10 µl of Laemmli’s SDS reducing buffer was added to each solution. Samples were boiled for 10 minutes at 99 °C then run on a 10–20% Tricine gel at 120 V. The gel was allowed to fix overnight in a 0.0125% glutaraldehyde in PBS. Gels were stained using a Pierce® Silver Stain kit (Cat# 24600).

Biodistribution analysis. Animal experiment. 6–8 week old female Syrian golden hamsters, 3 animals per group, were intraperitoneally injected with peptides (2 mg/kg) in 400 µL of water for injection (Aguettant). At each time point, blood was collected in EDTA vacutainer tubes from all animals of the corresponding group, tubes were centrifuged for 10 min at 2000 RPM, and plasma was transferred into new tubes and conserved at −20 °C for use in ELISA. At 24 h, organs from each animal were collected and separated in two: one half was conserved at −80 °C for ELISA, the other half frozen in cold isopentane on dry ice and placed at −80 °C for cryosectioning. Animals were bred at the animal facility in UMDNJ Newark and the protocols were approved by the Institutional Animal Care and Use Committee (IACUC Approval for Protocol Amendment #P129A1). All the experiments were performed in accordance with the relevant guidelines and regulations.

Preparation of organs for ELISA. Each frozen organ was weighed and mixed into 1X PBS (1:1, v/v) using an ultra turrax homogenizer. Samples were then treated with acetonitrile/TFA 1% (1:4, v/v) for 1 h on a wheel at 4 °C and then centrifuged for 10 min at 8000 rpm. Supernatant fluids were collected for ELISA.

ELISA. 96 well plates Maxisorp (Nunc) were coated overnight with purified goat anti-HPIV3 F HRC antibodies in carbonate/bicarbonate buffer pH = 7.4 (20 µg/ml). Plates were then washed twice in 1X PBS and blocked in 3% BSA/1X PBS for 30 min. The blocking buffer was replaced by 2 dilutions of each sample in 3% BSA/1X PBS in duplicate and incubated for 1.5 h at room temperature (RT). Wells were washed 3 times in 1X PBS, and developed with purified rabbit anti-HPIV3 F HRC antibodies conjugated to peroxidase (1/1500) in 3% BSA/1X PBS for 1 h at RT, followed by 5 washes and incubation with the Sigmafast OPD substrate system (Sigma-Aldrich, France), and stopped with sulfuric acid (12%). The optical density was read at 492 nm.

Immunofluorescence. The cryo-sections were dried for 30 min and fixed in a 4% formalin solution. After multiple washes in PBS, saturation was performed using PBS/4% FBS (30 min at RT) before incubation with specific rabbit anti-HPIV3 F HRC antibody (overnight at 4 °C) in PBS/4% FBS. After multiple washes, tissue sections were incubated with the secondary goat anti-rabbit antibody conjugated with Alexa 488, in PBS/4% FBS (2 h, RT). The nuclei were counterstained with DAPI. After multiple washes in PBS, mounting was performed using Fluoroprep (BioMérieux). Brain sections were analyzed using an Axiosplan 2 imaging microscope (Zeiss).

Golden hamster infection. Eight-week-old female Syrian golden hamsters (Mesocricetus auratus, Janvier, France), randomly distributed into cages by animal care takers, were anesthetized and infected intraperitoneally (i.p.) with 0.4 mL of NIV (100LD50) in BSL-4 conditions. Groups of 6 animals were treated daily with i.p. injections of peptide (2 mg/kg) for 10 days, starting from the day of infection, or received the vehicle in the untreated group without formal randomization. The animals were followed daily for 3 weeks in a blinded fashion.

Cotton rat infection. Inbred cotton rats were obtained from Harlan (Indianapolis, IN). Female animals, 7 weeks of age, were randomly distributed into cages by animal care takers. After acclimatization of one week, cages of cotton rats were grouped without formal randomization into treatment groups and infected with 106 pfu intranasally (i.n.), as previously described12,41. Groups of 4 animals were infected with the indicated virus and treated s.q. with 4 mg/kg/day of peptide, 2 doses per day, for day −1 to day 2 after infection. Group size was based on power analysis to determine a difference in treatment of at least one log10 in viral titer. Viral titers were determined 3 days post infection as previously described47. No samples were excluded from the analysis. No significant variance between groups was detected and samples were analyzed in a not blinded fashion. Animal work was approved by the Institutional Animal Care and Use Committee of the Ohio State University, and were performed in accordance with the relevant guidelines and regulations.

Statistical Analysis. All data were normally distributed with equal variance. Data are described as mean ± s.d. unless otherwise stated. For the peptide aggregation experiments, a 2-way ANOVA analysis was performed to distinguish different peptides and concentrations. Bonferroni post-tests were performed to compare replicate means. The statistical analysis performed on in vivo experiments for comparison of HPIV3 viral titers in cotton rats lungs were based on the non-parametric Mann–Whitney U-test, and Mantel-Cox analysis for comparison of survival curves in NIV infected golden hamsters. All the data and statistical tests were performed in Prism 5 (GraphPad Software, La Jolla, CA).
References

1. J. A. Englund & A. Moscona. In *Viral Infections of Humans* R. A. Kaishow, L. R. Stanberry, J. W. Le Duc, Eds, pp. 579–600 (Springer, New York, 2014).
2. J. F. Drexl et al. Bats host major mammalian paramyxoviruses. *Nat Commun* 3, 796 (2012).
3. G. A. Marsh et al. Cedar virus: a novel Henipavirus isolated from Australian bats. *PLoS Pathog* 8, e1002836 (2012).
4. Z. Wu et al. Novel Henipa-like virus, Mojiang Paramyxovirus, in rats, China, 2012. *Emerg Infect Dis* 20, 1064–1066 (2014).
5. S. C. Harrison. Viral membrane fusion. *Nat Struct Mol Biol* 15, 696–698 (2008).
6. M. Porotto et al. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. *PLoS Pathog* 6, e1001168 (2010).
7. H. Badani, R. F. Garry & W. C. Wimley. Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity. *Biochim Biophys Acta* 1838, 2180–2197 (2014).
8. M. Porotto et al. Viral entry inhibitors targeted to the membrane site of action. *J Virol* 84, 6760–6768 (2010).
9. M. Porotto et al. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. *J Virol* 81, 10567–10574 (2007).
10. A. Pessi et al. A general strategy to endow naturally occurring membrane-protein-derived peptides with potent antiviral activity. *PLoS One* 7, e36833 (2012).
11. J. C. Welsch et al. Fatal measles virus infection prevented by brain-penetrant fusion inhibitors. *J Virol* 87, 13785–13794 (2013).
12. M. Porotto et al. Spring-loaded model revisited: paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein. *J Virol* 85, 12867–12880 (2011).
13. O. Greengard, N. Poltoratskaia, E. Leikina, J. Zimmerberg & A. Moscona. The anti-influenza virus agent 4-GU-DANA (Zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. *J Virol* 74, 11108–11114 (2000).
14. M. Murrell, M. Porotto, T. Weber, O. Greengard & A. Moscona. Mutations in human parainfluenza virus type 3 HA causing increased receptor binding activity and resistance to the transition state sialic acid analogue 4-GU-DANA (zanamivir). *J Virol* 77, 309–317 (2003).
15. A. Hollmann, P. M. Matos, M. T. Augusto, M. A. Castanho & N. C. Santos. Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action. *PLoS One* 8, e60302 (2013).
16. M. T. Augusto et al. Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure. *J Antimicrob Chemother* 69, 1286–1297 (2014).
17. P. M. Matos, M. A. Castanho & N. C. Santos. HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes. *PLoS One* 5, e9830 (2010).
18. S. G. Palmer et al. Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for *in vivo* infection. *J Virol* 88, 13495–13502 (2014).
19. C. Mathieu et al. Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptides. *J Virol* 89, 1143–1155 (2015).
20. I. W. Hamley. PEG–peptide conjugates. *Biomacromolecules* 15, 1543–1559 (2014).
21. C. D. Higgins, J. F. Koelhoffer, K. Chandran & J. R. Lai. C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking. *Bioorg Med Chem Lett* 23, 5356–5360 (2013).
22. H. S. Yim, R. G. Paterson, X. Wen, R. A. Lamb & T. S. Jardetzky. Structure of the uncleaved ectodomain of the paramyxovirus (HPIV3) fusion protein. *Proc Natl Acad Sci USA* 102, 9288–9293 (2005).
23. C. G. Li et al. A cholesterol tag at the N terminus of the relatively broad-spectrum fusion inhibitor peptide targets an earlier stage of fusion glycoprotein activation and increases the peptide’s antiviral potency *in vivo*. *J Virol* 87, 9223–9232 (2013).
24. P. Ingallisella et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. *Proc Natl Acad Sci USA* 106, 5801–5806 (2009).
25. L. Zhang et al. Infection of ciliated cells by human parainfluenza virus type 3 in an *in vitro* model of human airway epithelium. *J Virol* 79, 1113–1124 (2005).
26. V. Guillaume et al. Nipah virus vaccination and passive protection studies in a hamster model. *J Virol* 78, 834–840 (2004).
27. P. Moosmann & S. Rusconi. Alpha complementation of LacZ in mammalian cells. *Nucleic acids research* 24, 1171–1172 (1996).
28. M. Porotto, M. Fornabaio, G. E. Kellogg & A. Moscona. A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism. *J Virol* 81, 3216–3228 (2007).
29. A. Talekar et al. Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment. *PLoS One* 7, e30538 (2012).
30. M. Porotto et al. Simulating henipavirus multicopy replication in a screening assay leads to identification of a promising candidate for therapy. *J Virol* 83, 5148–5155 (2009).
31. L. D. Mayer, M. J. Hope & P. R. Colis. Vesicles of variable sizes produced by a rapid extrusion procedure. *Biochim Biophys Acta* 858, 161–168 (1986).
32. F. Szoka et al. Preparation of unilamellar liposomes of intermediate size (0.1–0.2 mum) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. *Biochim Biophys Acta* 601, 559–571 (1980).
33. M. Kubista, R. Sjoback, S. Eriksson & B. Albinsson. Experimental Correction for the Inner-Filter Effect in Fluorescence-Spectra. *Analyst* 119, 417–419 (1994).
34. A. S. Ladokhin, S. Jayasinghe & S. H. White. How to measure and analyse tryptophan fluorescence in membranes properly, and why bother? *Anal Chem* 285, 235–245 (2004).
35. S. Veiga et al. Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions. *Biochim Biophys Acta* 1760, 55–61 (2006).
36. S. T. Henriques, L. K. Pattenden, M. J. Aguilar & M. A. Castanho. PrP(106-126) does not interact with membranes under physiological conditions. *Biophys* 95, 1877–1889 (2008).
37. X. Hong et al. Intracellular free calcium mediates glioma cell detachment and cytotoxicity after photodynamic therapy. *Lasers Med Sci* 24, 777–786 (2009).
38. P. M. Matos, H. G. Franquelim, M. A. Castanho & N. C. Santos. Quantitative assessment of peptide-lipid interactions. Ubiquitous fluorescence methodologies. *Biochim Biophys Acta* 1798, 1999–2012 (2010).
39. R. J. Clarke & D. J. Kane. Optical detection of membrane dipole potential: avoidance of fluidity and dye-induced effects. *Biochim Biophys Acta* 1323, 223–239 (1997).
40. J. Cladera & P. O'Shea. Intramembrane molecular dipoles affect the membrane insertion and folding of a model amphipilic peptide. *Biochim Biophys Acta* 74, 2343–2442 (1998).
41. M. Hakelberg & B. Kol. *Chemistry Today* 25, 48–53 (2007).
42. L. M. Palermo et al. Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity. *J Virol* 83, 6900–6908 (2009).
43. A. Moscona et al. A Recombinant Sialidase Fusion Protein Effectively Inhibits Human Parainfluenza Viral Infection *In Vitro* and *In Vivo*. *J Infect Dis* (2010).
Acknowledgements
This research was funded by NIH grants RO1AI114736, R33AI01333, and RO1AI031971 to A.M. and by ANR-ASTRID-2011. M.T.A. has fellowship support SFRH/BD/95624/2013 from Fundação para a Ciência e Tecnologia-Ministério da Educação e Ciência (FCT-MEC, Portugal) and support from Fundação Luso Americana para o Desenvolvimento (FLAD) Proj. 4/2016. We thank Peter Collins and Alex Bukreyev (National Institutes for Allergy and Infectious Diseases, National Institutes of Health, USA) for the recombinant HPIV3 expressing enhanced GFP.

Author Contributions
A.M., N.C.S., M.P, M.A.R.B.C., S.N. and B.H. supervised research. A.M., N.C.S. and M.P. conceived and designed the experiments. C.M., M.T.A., L.M.P., G.S., S.M. and D.H. performed the experiments. C.M., M.T.A., A.M., N.C.S., M.P, M.A.R.B.C., S.N. and B.H. analyzed the data. A.M., C.M., M.P, N.C.S. and M.T.A. wrote the paper.

Additional Information
Competing Interests: The authors declare no competing financial interests.

How to cite this article: Mathieu, C. et al. Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides. Sci. Rep. 7, 43610; doi: 10.1038/srep43610 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017